Journal of the American Society of Hypertension
Volume 3, Issue 4 , Pages 245-259 , July 2009

Cardiovascular consequences of drugs used for the treatment of diabetes: potential promise of incretin—based therapies

  • Kiwon Ban, MSc

      Affiliations

    • Heart & Stroke Richard Lewar Centre of Excellence for Cardiovascular Research, University of Toronto, Toronto, Ontario, Canada
    • Department of Physiology, University of Toronto, Toronto, Ontario, Canada
    • Toronto General Hospital Research Institute, Toronto, Ontario, Canada
    • ,
  • Sonya Hui, BSc

      Affiliations

    • Heart & Stroke Richard Lewar Centre of Excellence for Cardiovascular Research, University of Toronto, Toronto, Ontario, Canada
    • Department of Physiology, University of Toronto, Toronto, Ontario, Canada
    • Toronto General Hospital Research Institute, Toronto, Ontario, Canada
    • ,
  • Daniel J. Drucker, MD

      Affiliations

    • Department of Medicine, University of Toronto, Toronto, Ontario, Canada
    • Banting & Best Diabetes Centre, University of Toronto, Toronto, Ontario, Canada
    • Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada
    • ,
  • Mansoor Husain, MD

      Affiliations

    • Heart & Stroke Richard Lewar Centre of Excellence for Cardiovascular Research, University of Toronto, Toronto, Ontario, Canada
    • Department of Physiology, University of Toronto, Toronto, Ontario, Canada
    • Department of Medicine, University of Toronto, Toronto, Ontario, Canada
    • Toronto General Hospital Research Institute, Toronto, Ontario, Canada
    • Corresponding Author InformationCorresponding author: Mansoor Husain, MD, Toronto General Hospital Research Institute 200 Elizabeth Street, TMDT3-909, Toronto, Ontario, Canada M5G-1C4. Tel: 416-581-7488; fax: 416-340-4021.

Received 5 December 2008 ,Accepted 6 April 2009.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 This study was supported in part by an Operating Grant from the Heart & Stroke Foundation of Ontario (HSFO; NA5926) awarded to Drs. Husain and Drucker; the Canada Research Chairs Program (Dr. Drucker) and a Career Investigator Award from the HSFO (Dr. Husain) (CI-5503).

 Dr. Drucker has served as an advisor or consultant within the past 12 months to Amgen Inc, Amylin Pharmaceuticals, Arisaph Pharmaceuticals Inc, Chugai Inc, Conjuchem Inc, Eli Lilly Inc, Emisphere Technologies Inc, GlaxoSmithKline, Glenmark Pharmaceuticals, Isis Pharmaceuticals Inc, Johnson & Johnson, Merck Research Laboratories, Novartis Pharmaceuticals, Novo Nordisk Inc, NPS Pharmaceuticals Inc, Phenomix Inc, Takeda, and Transition Pharmaceuticals Inc. Dr. Husain has served as a consultant within the past 12 months to Merck Research Laboratories.

 Conflict of interest: none.

PII: S1933-1711(09)00045-X

doi: 10.1016/j.jash.2009.04.001

Journal of the American Society of Hypertension
Volume 3, Issue 4 , Pages 245-259 , July 2009

Article Tools

* Image Usage & Resolution